Hodgkin's lymphoma Posts - Page 12 of 38 on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Can PET/CT scanning during chemotherapy help predict lung side effects in patients with Hodgkin lymphoma?

Can PET/CT scanning during chemotherapy help predict lung side effects in patients with Hodgkin lymphoma?

Posted by on Sep 20, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated whether FDG-PET/CT scanning could help predict side effects from bleomycin (Blenoxane) in patients with Hodgkin lymphoma (HL) treated with ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine). This study concluded that this type of scanning could help predict lung side effects earlier than other clinical...

Read More

Searching for patients with leukemia or lymphoma to test modified stem cell transplants donated by relatives

Posted by on Sep 20, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is examining the effectiveness of modified stem cell transplants (SCT) donated by patient relatives, which have certain immune cells removed to prevent transplant rejection in patients with leukemia and lymphoma. The main outcome will be the maximum dose of SCT that can be given safely and is effective. This study is...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Evaluating pembrolizumab for patients with reoccurring classical Hodgkin’s lymphoma

Evaluating pembrolizumab for patients with reoccurring classical Hodgkin’s lymphoma

Posted by on Sep 2, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with classical Hodgkin’s lymphoma (cHL) that came back after initial treatment. This study concluded that pembrolizumab was effective for these patients, with manageable side effects. Some background First-line chemotherapy is highly...

Read More

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Posted by on Aug 23, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....

Read More

Evaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma

Evaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma

Posted by on Aug 19, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....

Read More

How common is blood clotting in patients with Hodgkin’s lymphoma?

How common is blood clotting in patients with Hodgkin’s lymphoma?

Posted by on Aug 8, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated how often patients Hodgkin’s lymphoma (HL) experienced blood clots and what factors increased the risk of blood clots.  The authors found that patients with advanced HL were more likely to develop blood clots, particularly during chemotherapy, and that age, smoking status, and treatment frequency increased...

Read More

Does the modification of chemotherapy reduce heart disease side effects in patients with Hodgkin lymphoma?

Does the modification of chemotherapy reduce heart disease side effects in patients with Hodgkin lymphoma?

Posted by on Aug 4, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if a modified version of doxorubicin (Adriamycin) in ABVD chemotherapy was safe and effective in patients with Hodgkin’s lymphoma who had heart disease. This study found that this regimen was safer and just as effective as conventional ABVD. Some background Hodgkin’s lymphoma (HL) is a cancer of white...

Read More

Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.

Posted by on Jul 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...

Read More